Independent Validation of a Unifying Prognostic Model for Intracranial and Extracranial Metastasis-directed Radiotherapy

Background/Aim: The aim of this study was to analyze the validity of a unifying prognostic model, originally developed by Kowalchuk et al., because relevant variations in clinical practice and observed survival may impact on the performance of predictive tools. Patients and Methods: Retrospectively, data from a single institution were analyzed. The study included 253 patients managed with radiotherapy for spine and/or brain metastases. The Kowalchuk et al. score [3 parameters including performance status, number of organ systems involved with disease outside of the organ system of the treatment target, and treatment of intracranial target(s)] was assigned and the resulting prognostic strata compared. Results: The decision tool developed by Kowalchuk et al. performed well, e.g., in terms of 2-year survival. Complementary information could be obtained by analyses of blood test results such as hemoglobin, albumin, and C-reactive protein. Conclusion: The new unifying score emerged as a valid prognostic model in our external validation database.

[1]  C. Nieder,et al.  The LabPS score , 2023 .

[2]  C. Nieder,et al.  Palliative appropriateness criteria: external validation of a new method to evaluate the suitability of palliative radiotherapy fractionation , 2023, Strahlentherapie und Onkologie.

[3]  Sean S. Park,et al.  Development and validation of a unifying pre-treatment decision tool for intracranial and extracranial metastasis-directed radiotherapy , 2022, Frontiers in Oncology.

[4]  A. Spektor,et al.  Patient and Treatment Factors Associated with Improved Local Control and Survival in Oligometastatic Bone Disease: Results from a Large Single-Institution Experience Using Stereotactic Body Radiation Therapy. , 2022, International journal of radiation oncology, biology, physics.

[5]  Sanjeev Sharma,et al.  Stereotactic Body Radiation Therapy (SBRT) for Spinal Metastases , 2022, American journal of clinical oncology.

[6]  C. Nieder,et al.  Independent External Validation of the METSSS Model Predicting Survival After Palliative Radiotherapy , 2022, AntiCancer Research.

[7]  Neha M Jain,et al.  Improving Survival Prognostication in Patients With Metastatic Cancer Through Clinical Judgment , 2022, AntiCancer Research.

[8]  C. Nieder,et al.  The LabBM score is an excellent survival prediction tool in patients undergoing palliative radiotherapy , 2021, Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology.

[9]  M. Mehta,et al.  Assessment of extracranial metastatic disease in patients with brain metastases: how much effort is needed in the context of evolving survival prediction models? , 2021, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[10]  C. Nieder,et al.  Independent Validation of a Comprehensive Machine Learning Approach Predicting Survival After Radiotherapy for Bone Metastases , 2021, AntiCancer Research.

[11]  A. Louie,et al.  Stereotactic Radiosurgery and Stereotactic Body Radiotherapy in the Management of Oligometastatic Disease. , 2020, Clinical oncology (Royal College of Radiologists (Great Britain)).

[12]  M. Rajagopalan,et al.  External validation of life expectancy prognostic models in patients evaluated for palliative radiotherapy at the end‐of‐life , 2020, Cancer medicine.

[13]  Thomas J. Smith,et al.  Developing an Improved Statistical Approach for Survival Estimation in Bone Metastases Management: The Bone Metastases Ensemble Trees for Survival (BMETS) Model. , 2020, International journal of radiation oncology, biology, physics.

[14]  S. Kalkanis,et al.  Sarcopenia Predicts Overall Survival in Patients with Lung, Breast, Prostate, or Myeloma Spine Metastases Undergoing Stereotactic Body Radiation Therapy (SBRT), Independent of Histology. , 2020, Neurosurgery.

[15]  V. Verma,et al.  Principles and Applications of Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy. , 2019, Hematology/oncology clinics of North America.

[16]  J. Debus,et al.  Quality of Life and Radiation-induced Late Toxicity Following Intensity-modulated Versus Three-dimensional Conformal Radiotherapy for Patients with Spinal Bone Metastases: Results of a Randomized Trial , 2018, AntiCancer Research.

[17]  M. Mehta,et al.  Prognostic and predictive factors in patients with brain metastases from solid tumors: A review of published nomograms. , 2018, Critical reviews in oncology/hematology.

[18]  E. Bruera,et al.  Palliative radiation therapy in the last 30 days of life: A systematic review. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[19]  T. Holland-Letz,et al.  Combining standard clinical blood values for improving survival prediction in patients with newly diagnosed brain metastases—development and validation of the LabBM score , 2017, Neuro-oncology.

[20]  P. Hoskin,et al.  A review of patterns of practice and clinical guidelines in the palliative radiation treatment of uncomplicated bone metastases. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[21]  C. Marijnen,et al.  An easy tool to predict survival in patients receiving radiation therapy for painful bone metastases. , 2014, International journal of radiation oncology, biology, physics.

[22]  R. Bremnes,et al.  Prognostic Scores in Patients with Brain Metastases from Non-small Cell Lung Cancer , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[23]  I. Tannock,et al.  Predictive model for survival in patients with advanced cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  C. Nieder,et al.  Palliative Radiotherapy for Non-metastatic Non-small-cell Lung Cancer: Impact of Blood Test Results on Survival , 2023, In Vivo.